Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UCI Health Laguna Hills Laguna Hills, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 27 locations
View Trial Details
Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +16 more
Locations
  • The University of Arizona Cancer Center - North Campus /ID# 242219 Tucson, Arizona, United States
  • Yale University School of Medicine /ID# 242089 New Haven, Connecticut, United States
  • Christiana Care Health Service /ID# 242301 Newark, Delaware, United States
  • Tampa General Hospital /ID# 246748 Tampa, Florida, United States
View all 76 locations
View Trial Details
Active, not recruiting

Lenalidomide Maintenance in Plasma Cell Myeloma

NCT02538198

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
View Trial Details
Active, not recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Community Cancer Institute (CCI) Fresno, California, United States
  • Baptist - MD Anderson Cancer Center Jacksonville, Florida, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
View all 63 locations
View Trial Details
Active, not recruiting

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

NCT03179917

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • University of Miami Miami, Florida, United States
  • Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
View Trial Details
Active, not recruiting

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

NCT03681535

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital Weymouth, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Active, not recruiting

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

NCT04447768

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +14 more
Locations
  • Stanford University Medical Center (Data collection only) Stanford, California, United States
  • Memorial Sloan Kettering Basking Ridge (All protocol activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Commack (All protocol activities) Commack, New York, United States
View Trial Details
Active, not recruiting

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03331198

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +14 more
Locations
  • Local Institution - 0006 Birmingham, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Local Institution - 0043 Gilbert, Arizona, United States
View all 84 locations
View Trial Details

Related conditions